Skip to main content
 

SER-287 (SERES-101 study)

SERES-101 is a Phase 1b clinical study evaluating the safety and efficacy of SER-287 versus placebo, in adults with mild-to-moderate Ulcerative Colitis (UC). This study is called a Phase 1b study because it was primarily intended to assess the safety and tolerability of SER-287 when taken by adults, but it will also attempt to identify preliminary signs of efficacy in patients with UC. The full name of the clinical study is: “A Phase 1b Multiple Dose Study to Evaluate the Safety, Tolerability, and Microbiome Dynamics of SER-287 in Subjects with Mild-to-Moderate Ulcerative Colitis.”

Seres reported positive results of its Phase 1b study of SER-287 in patients with UC. Future development in other forms of IBD are under consideration.

About Ulcerative Colitis

Ulcerative Colitis is a chronic inflammatory condition of the colon, leading to episodes of bloody diarrhea and urgency. The disease mostly affects young and middle-aged individuals. The cause of Ulcerative Colitis is largely unknown. While genetic factors contribute to disease risk, an abnormal relationship between the immune system and intestinal bacteria may also play a role in triggering the disease.

In several previously reported studies, some UC patients with mild-to-moderate disease administered bacteria through fecal microbiota transplant from a healthy donor experienced improvements in their UC symptoms, suggesting that changes in the bacteria may contribute to this clinical response.

SERES-101 Clinical Trial
Learn more about our Phase 1b Trial >

Enrollment is now complete. Please check back.

SERES Therapeutics Pipeline
Learn more about Seres Therapeutics Pipeline >

SER-109 for Recurrent C. Diff. Infection

Learn more about our Phase 3 ECOSPORTM trial

More

Back to top